Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nogapendekin Alfa Inbakicept, PD-L1 t-haNK, Bevacizumab and TTFields in Recurrent or Progressive Glioblastoma
NCT06061809Phase 2Active, not recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2024
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, PD-L1 t-haNK in glioblastoma (GBM), sponsored by ImmunityBio, Inc.. Started Aug 2024; status: active, not recruiting.
02
Drugs
nogapendekin alfa inbakiceptPD-L1 t-haNK
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06061809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061809.